Similar pattern seen for medication overuse headache versus matched controls not receiving SMT
WEDNESDAY, Dec. 11, 2024 (HealthDay News) — Adults receiving chiropractic spinal manipulative therapy (SMT) for tension-type headache have a significantly lower likelihood of butalbital prescription, according to a study published online Nov. 29 in Health Science Reports.
Robert J. Trager, D.C., from the Case Western Reserve University School of Medicine in Cleveland, and colleagues assessed whether receiving chiropractic SMT for tension-type headache impacts receipt of butalbital prescription. The analysis included 3,116 matched patients with tension-type headache receiving and not receiving SMT.
The researchers found that the incidence of butalbital prescription was lower in the SMT cohort versus the non-SMT cohort (SMT: 1.7 percent; non-SMT: 3.8 percent; risk ratio, 0.46). The SMT cohort also had a lower incidence of medication overuse headache versus the non-SMT cohort (SMT: 0.5 percent; non-SMT: 1.2 percent; risk ratio, 0.44).
“Adults receiving chiropractic SMT had a significantly lower likelihood of butalbital prescription and, tentatively, medication overuse headache compared to matched controls not receiving SMTs,” the authors write. “These findings reinforce clinical practice guidelines already recommending SMT for tension-type headache. However, additional research is needed to corroborate our results and examine the association between a broader variety of nonpharmacologic interventions and butalbital prescription and medication overuse headache.”
Long-Term Medication Adherence Tied to Lower Cardiovascular Event Rate in Type 2 Diabetes
Once-Weekly Oral Islatravir-Lenacapavir Noninferior to Daily B/F/TAF in HIV
28 Percent of U.S. Adults With HTN Eligible for Treatment Under New Guidelines
Enfortumab Vedotin-Pembrolizumab More Effective for MIBC Than Cisplatin-Gemcitabine
Achieving PSA <0.2 ng/mL Improves Survival in Metastatic Castration-Sensitive Prostate Cancer
Cretostimogene Promising for High-Risk, Non-Muscle-Invasive Bladder Cancer
Omalizumab, Multiallergen OIT Both Viable for Multifood Allergy Treatment
Indefinite-Duration Maintenance Therapy No Better Than Fixed-Duration Therapy in Multiple Myeloma